Abstract
The efficient inhibition of angiogenesis is considered as a promising strategy for the treatment of angiogenesis-related diseases including cancer. Herein, we report that embellistatin, a bicyclic ketone compound known as a microtubule polymerization inhibitor, exhibits anti-angiogenic activity. Embellistatin inhibited in vitro angiogenesis of bovine aortic endothelial cells (BAECs) such as bFGF-induced invasion and tube formation as well as bFGF-induced mouse corneal angiogenesis in vivo. Notably, embellistatin exhibited stronger inhibition activity for the growth of BAECs than that of normal and cancer cell lines. Cell cycle analysis revealed that the compound arrests cell cycle at G2/M phase, which is associated with the increased expression of p21WAF1 and p53 partly. These results demonstrate that embellistatin may serve the basis for the development of new anti-angiogenic agents.
| Original language | English |
|---|---|
| Pages (from-to) | 376-380 |
| Number of pages | 5 |
| Journal | Biochemical and Biophysical Research Communications |
| Volume | 353 |
| Issue number | 2 |
| DOIs | |
| Publication status | Published - 2007 Feb 9 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Biophysics
- Biochemistry
- Molecular Biology
- Cell Biology
Cite this
}
Embellistatin, a microtubule polymerization inhibitor, inhibits angiogenesis both in vitro and in vivo. / Jung, Hye Jin; Shim, Joong Sup; Lee, Hyang Burm; Kim, Chang Jin; Kuwano, Takashi; Ono, Mayumi; Kwon, Ho Jeong.
In: Biochemical and Biophysical Research Communications, Vol. 353, No. 2, 09.02.2007, p. 376-380.Research output: Contribution to journal › Article
TY - JOUR
T1 - Embellistatin, a microtubule polymerization inhibitor, inhibits angiogenesis both in vitro and in vivo
AU - Jung, Hye Jin
AU - Shim, Joong Sup
AU - Lee, Hyang Burm
AU - Kim, Chang Jin
AU - Kuwano, Takashi
AU - Ono, Mayumi
AU - Kwon, Ho Jeong
PY - 2007/2/9
Y1 - 2007/2/9
N2 - The efficient inhibition of angiogenesis is considered as a promising strategy for the treatment of angiogenesis-related diseases including cancer. Herein, we report that embellistatin, a bicyclic ketone compound known as a microtubule polymerization inhibitor, exhibits anti-angiogenic activity. Embellistatin inhibited in vitro angiogenesis of bovine aortic endothelial cells (BAECs) such as bFGF-induced invasion and tube formation as well as bFGF-induced mouse corneal angiogenesis in vivo. Notably, embellistatin exhibited stronger inhibition activity for the growth of BAECs than that of normal and cancer cell lines. Cell cycle analysis revealed that the compound arrests cell cycle at G2/M phase, which is associated with the increased expression of p21WAF1 and p53 partly. These results demonstrate that embellistatin may serve the basis for the development of new anti-angiogenic agents.
AB - The efficient inhibition of angiogenesis is considered as a promising strategy for the treatment of angiogenesis-related diseases including cancer. Herein, we report that embellistatin, a bicyclic ketone compound known as a microtubule polymerization inhibitor, exhibits anti-angiogenic activity. Embellistatin inhibited in vitro angiogenesis of bovine aortic endothelial cells (BAECs) such as bFGF-induced invasion and tube formation as well as bFGF-induced mouse corneal angiogenesis in vivo. Notably, embellistatin exhibited stronger inhibition activity for the growth of BAECs than that of normal and cancer cell lines. Cell cycle analysis revealed that the compound arrests cell cycle at G2/M phase, which is associated with the increased expression of p21WAF1 and p53 partly. These results demonstrate that embellistatin may serve the basis for the development of new anti-angiogenic agents.
UR - http://www.scopus.com/inward/record.url?scp=33845880644&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33845880644&partnerID=8YFLogxK
U2 - 10.1016/j.bbrc.2006.12.026
DO - 10.1016/j.bbrc.2006.12.026
M3 - Article
C2 - 17184734
AN - SCOPUS:33845880644
VL - 353
SP - 376
EP - 380
JO - Biochemical and Biophysical Research Communications
JF - Biochemical and Biophysical Research Communications
SN - 0006-291X
IS - 2
ER -